Several organizations have filed amicus briefs in support of Dr. Sue Sisley, who is petitioning the Ninth Circuit to rule that the DEA’s five-part test to assess if a drug has medical use and can be rescheduled is arbitrary and capricious.
Rice University’s Baker Institute, the Iraq and Afghanistan Veterans of America (IAVA) and several doctors filed the amicus briefs Oct. 6 in support of Sisley’s petition, which ultimately seeks to facilitate medical cannabis research for veterans suffering from post-traumatic stress disorder (PTSD).
The briefs urge the court to grant Sisley’s Petition for Review, which would allow researchers to study the effects of cannabis as a treatment for PTSD.
Cannabis has long been classified as a Schedule I substance under the Controlled Substances Act, which severely limits researchers’ ability to access cannabis for clinical trials.
“The Veterans Administration can’t do anything with medical marijuana because it’s a Schedule I substance, [and] Sue Sisley and her company couldn’t go and get marijuana for her clinical trial from anyone other than a government-authorized supplier because it is a Schedule I drug,” Susman Godfrey attorney Erica Harris, who represented IAVA in its amicus brief in support of Sisley’s petition, told Cannabis Business Times and Cannabis Dispensary.
Sisley and other researchers have been critical of the quality of the medical cannabis produced by the University of Mississippi, the only organization licensed to grow cannabis for medical research in the U.S.
Sisley and her team sued the Drug Enforcement Administration (DEA) and the Justice Department last